Analysts forecast that LeMaitre Vascular, Inc. (NASDAQ:LMAT) will post $0.42 earnings per share for the current fiscal quarter, Zacks reports. Two analysts have made estimates for LeMaitre Vascular’s earnings, with the lowest EPS estimate coming in at $0.42 and the highest estimate coming in at $0.43. LeMaitre Vascular posted earnings per share of $0.23 during the same quarter last year, which indicates a positive year over year growth rate of 82.6%. The firm is expected to report its next earnings results on Thursday, July 26th.
According to Zacks, analysts expect that LeMaitre Vascular will report full-year earnings of $1.08 per share for the current year, with EPS estimates ranging from $1.06 to $1.11. For the next fiscal year, analysts forecast that the firm will post earnings of $1.00 per share, with EPS estimates ranging from $0.99 to $1.02. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow LeMaitre Vascular.
LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Wednesday, April 25th. The medical instruments supplier reported $0.19 EPS for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.02). LeMaitre Vascular had a net margin of 17.34% and a return on equity of 16.66%. The firm had revenue of $25.99 million for the quarter, compared to analysts’ expectations of $26.42 million. During the same quarter last year, the business earned $0.16 earnings per share. The business’s revenue was up 7.8% compared to the same quarter last year.
LMAT has been the subject of a number of research analyst reports. BidaskClub upgraded LeMaitre Vascular from a “strong sell” rating to a “sell” rating in a report on Tuesday, January 16th. Canaccord Genuity restated a “hold” rating and set a $33.00 target price on shares of LeMaitre Vascular in a report on Friday, February 23rd. Zacks Investment Research upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $40.00 target price for the company in a report on Wednesday, February 28th. ValuEngine upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Wednesday, April 4th. Finally, Stifel Nicolaus cut LeMaitre Vascular from a “buy” rating to a “hold” rating and lowered their target price for the company from $40.00 to $34.00 in a report on Thursday, April 26th. Six equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $35.33.
LeMaitre Vascular stock traded up $0.22 during midday trading on Friday, reaching $33.77. 4,590 shares of the stock traded hands, compared to its average volume of 155,904. LeMaitre Vascular has a 12-month low of $33.59 and a 12-month high of $34.05. The stock has a market capitalization of $643.68 million, a price-to-earnings ratio of 39.47, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 7th. Stockholders of record on Tuesday, May 22nd will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.83%. The ex-dividend date of this dividend is Monday, May 21st. LeMaitre Vascular’s payout ratio is presently 32.56%.
In other news, Chairman George W. Lemaitre sold 45,000 shares of LeMaitre Vascular stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $34.66, for a total value of $1,559,700.00. Following the completion of the transaction, the chairman now owns 3,225,709 shares in the company, valued at approximately $111,803,073.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO George W. Lemaitre sold 5,700 shares of LeMaitre Vascular stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $35.56, for a total value of $202,692.00. Following the completion of the transaction, the chief executive officer now owns 3,259,263 shares of the company’s stock, valued at approximately $115,899,392.28. The disclosure for this sale can be found here. Insiders sold a total of 143,080 shares of company stock valued at $5,045,159 in the last quarter. Company insiders own 20.30% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. boosted its stake in shares of LeMaitre Vascular by 73.8% in the 1st quarter. Victory Capital Management Inc. now owns 5,076 shares of the medical instruments supplier’s stock valued at $184,000 after buying an additional 2,156 shares during the period. BB&T Corp purchased a new position in shares of LeMaitre Vascular in the 4th quarter valued at about $202,000. Citadel Advisors LLC purchased a new position in shares of LeMaitre Vascular in the 1st quarter valued at about $241,000. Advisor Group Inc. boosted its stake in shares of LeMaitre Vascular by 28.3% in the 4th quarter. Advisor Group Inc. now owns 7,033 shares of the medical instruments supplier’s stock valued at $223,000 after buying an additional 1,550 shares during the period. Finally, MetLife Investment Advisors LLC purchased a new position in shares of LeMaitre Vascular in the 4th quarter valued at about $244,000. Institutional investors and hedge funds own 72.52% of the company’s stock.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.